Introduction Because “real-life” patients often do not meet the strict eligibility criteria of
clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal …

Background This population-wide retrospective, non-interventional registry study assessed
changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal …

Purpose A correlation, power and benchmarking analysis between progression-free and
overall survival (PFS, OS) of randomized trials with targeted agents or immunotherapy for …

Background Targeted therapies in metastatic renal cell carcinoma (mRCC) have been
approved based on registration clinical trials that have strict eligibility criteria. The clinical …

Background The aim of the RECCORD registry was to gather real-world UK data on the use
of targeted therapies in renal cell carcinoma (RCC) and assess clinical outcomes. Here …

Purpose: We assessed temporal shifts in the frequency of risk factors for patients with
metastatic renal cell carcinoma in a multicenter, international data set. Materials and …

Background Treatment decisions in routine clinical practice are based on reports of clinical
trials, which represent highly selected populations. Limited studies reported real-world …

Introduction: As new therapeutics for metastatic renal cell carcinoma (mRCC) are quickly
introduced to market, comparative randomized trial evidence guiding treatment decisions is …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

Conclusions This narrative review depicts a summary of the evidence base for treatment of
RCC. Management of RCC is a rapidly evolving and changing field. As a consequence …